s Foreword

As an Editor-in-Chief of the journal ‘Infectious Disorders - Drug Targets’, I am very pleased to announce that it is now an internationally well-recognized and competitive journal with an always growing audience in various areas of research, such as virology, bacteriology, medicinal chemistry, pharmacology, biochemistry, molecular biology and genomics. By publishing both timely in-depth review articles (see special issues) and original research works, it is actually an invaluable ‘tool’ that helps the scientists to update their education and to survey the main discoveries and developments in the variety of topics, which is often an asset to their own scientific research. Indeed, it appears to be of the utmost importance to cover the latest state of knowledge in each field to help researchers and clinicians opening new routes of investigation in this particularly ‘complex’ world of drug design, infectious diseases and related molecular targets. For 2012 (and upcoming years), we expect and strongly encourage the contribution of distinguished researchers and clinicians to the journal, which is a basis of its success and further development. Also, I would like to thank section editors and members of the editorial board for providing outstanding expertise in their respective fields; I congratulate Drs Matthew Honan and Ambreen Wasim (editorial office of Bentham Science Publishers) for the efficient promotion of our journal and their constant support and efforts to maintain its high standard. Finally, I wish the contributors and readers of the journal ‘Infectious Disorders - Drug Targets’ a happy and fruitful new year, expected to be rich in discoveries.